文献速递脑血管病

与缺血性卒中相关的药物:面向临床医生的综述

Drugs Associated With Ischemic Stroke: A Review for Clinicians.
PubMed 文献 · Stroke · 2021-08-18

该综述检索Pubmed/MEDLINE 1966至2020年数据,评估81种药物或药物类别与缺血性卒中的关联。结果发现促红细胞生成素、复方避孕药、口服雌激素替代疗法、贝伐珠单抗、他莫昔芬和抗精神病药有高度关联证据,而帕纳替尼、尼洛替尼、达芦那韦和促性腺激素释放激素激动剂为中度关联。

要点

  • 促红细胞生成素、复方避孕药、口服雌激素替代疗法、贝伐珠单抗、他莫昔芬和抗精神病药与缺血性卒中高度关联。
  • 帕纳替尼、尼洛替尼、达芦那韦和促性腺激素释放激素激动剂与缺血性卒中中度关联。
  • 药物剂量和治疗时长可能改变缺血性卒中风险。

核心结论

  • 有限数量的药物与缺血性卒中高度关联,部分药物存在潜在关联,其他药物数据不足。

研究设计与样本

  • 检索Pubmed/MEDLINE 1966至2020年文献,评估81种药物或药物类别,依据WHO ATC分类系统分组。

主要发现

  • 促红细胞生成素、复方避孕药、口服雌激素替代疗法、贝伐珠单抗、他莫昔芬和抗精神病药与缺血性卒中高度关联。
  • 帕纳替尼、尼洛替尼、达芦那韦和促性腺激素释放激素激动剂与缺血性卒中中度关联。
  • 药物剂量和治疗时长可能改变风险。

关键数值与推荐

  • 采用预设标准将关联证据水平从A(高度关联证据)至E(高度无关联证据)分级。

临床怎么用

  • 总结信息可帮助临床医生评估药物对缺血性卒中的贡献,更好地评估药物获益-风险比,并支持特定药物的使用决策。

局限性

  • 部分药物数据不足,无法归类风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Certain drugs may increase the risk of ischemic stroke (IS). Our goal was to review associations between frequently used drugs and IS. We created an initial list of frequently used drugs to search Pubmed/MEDLINE from 1966 to 2020 and reviewed phase III and IV data, case series, and drug authorities' safety warnings to assess a potential association with IS. Drugs were grouped according to the World Health Organization Anatomical Therapeutic Chemical Classification System. Predefined criteria were applied to establish a level of evidence for an association, from A (high level of evidence of association) to E (high level of evidence of absence of association). In addition, we assessed relative risks and reviewed potential mechanisms of IS facilitation. We assessed 81 drugs or drug classes from 11 World Health Organization Anatomical Therapeutic Chemical Groups. We identified a high level of association for erythropoietin, combined contraceptives, oral estrogen replacement therapy, bevacizumab, tamoxifen, and antipsychotics and a moderate level for ponatinib, nilotinib, darunavir, and gonadotropin-releasing hormone agonists. Drug dose and treatment duration may modify the risk. For a substantial number of drugs, we found no association, and for others, there were insufficient data to categorize risk. We identified a high level of association of IS with a limited number of drugs, a potential association with some, and a lack of data for others. The summarized information may help clinicians to estimate the contribution of a drug to an IS, to better assess drug benefit-risk ratios, and to support decisions about using specific drugs.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Marto JP, Strambo D, Livio F, et al. Drugs Associated With Ischemic Stroke: A Review for Clinicians. Stroke. 2021. PMID: 34404236. doi:10.1161/STROKEAHA.120.033272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。